{
"id":"mk19_bb_gi_s28",
"subspecialtyId":"gi",
"title":"Nonalcoholic Fatty Liver Disease",
"jsonContent":{
"type":"section",
"id":"mk19_bb_gi_s28",
"title":{
"__html":"Nonalcoholic Fatty Liver Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"946af2",
"children":[
"Nonalcoholic Fatty Liver Disease"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_gi_s28_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"0f1b97",
"children":[
{
"type":"abbreviation",
"title":"nonalcoholic fatty liver disease",
"children":[
"NAFLD"
]
},
" is the most common cause of abnormal liver test results. Most patients have insulin resistance, obesity, hypertriglyceridemia, and type 2 diabetes mellitus."
]
},
{
"type":"p",
"hlId":"716879",
"children":[
"Approximately 20% of patients with NAFLD have nonalcoholic steatohepatitis (NASH), characterized by hepatic steatosis, inflammation, and often fibrosis."
]
},
{
"type":"p",
"hlId":"f26a5d",
"children":[
"A presumptive diagnosis of NAFLD can be made in a patient with:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"cda157",
"children":[
"mildly elevated aminotransferase levels"
]
},
" ",
{
"type":"list-item",
"hlId":"b67bdc",
"children":[
"risk factors for NAFLD (diabetes, obesity, and hyperlipidemia)"
]
},
" ",
{
"type":"list-item",
"hlId":"c0325a",
"children":[
"hyperechoic pattern on ultrasonography or low-density parenchyma on CT"
]
},
" "
]
},
{
"type":"p",
"hlId":"1318a8",
"children":[
"The NAFLD fibrosis and fibrosis-4 scores use clinical data to identify patients at risk for advanced hepatic fibrosis. Transient elastography is obtained in patients with indeterminate or high-risk scores to assess for significant hepatic fibrosis. Liver biopsy is indicated when the diagnosis is in doubt or the presence of hepatic fibrosis cannot otherwise be determined."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_gi_s28_2",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"d6e674",
"children":[
"Treatment for NAFLD consists of controlling diabetes, obesity, and hyperlipidemia."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"0c0ec2",
"children":[
"No drugs are approved for the primary treatment of NAFLD."
]
},
" ",
{
"type":"list-item",
"hlId":"50721a",
"children":[
"Patients with fatty liver disease and elevated aminotransferase levels can be treated with statin therapy."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_gi_s28_3",
"title":{
"__html":"Test Yourself"
},
"titleNode":{
"type":"section-title",
"hlId":"7866cc",
"children":[
"Test Yourself"
]
},
"children":[
{
"type":"p",
"hlId":"61a55e",
"class":"test",
"children":[
"A 38-year-old woman with type 2 diabetes mellitus develops elevated aminotransferase levels. She has obesity. She does not use alcohol excessively. Serum ",
{
"type":"abbreviation",
"title":"aspartate aminotransferase",
"children":[
"AST"
]
},
" is 134 U/L and ",
{
"type":"abbreviation",
"title":"alanine aminotransferase",
"children":[
"ALT"
]
},
" is 147 U/L. Abdominal ultrasonography shows increased echogenicity of the liver."
]
},
{
"type":"p",
"hlId":"731f97",
"class":"test_answer",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Answer:"
]
},
" ",
"For diagnosis, choose NAFLD."
]
}
]
}
]
},
"tablesContent":{
}
}